Clinical Trial Search

Primary: Change From Baseline in Blood Eosinophil Levels at Week 12 (Day 84) — 0.43; 0.14; 0.12; 0.14 Proportion of Baseline blood eosinophil

Primary: Number of Spontaneous Bowel Movements in Patients With Multiple Sclerosis (MS)-Associated Constipation Per Day. — 3.4; 3.2 spontaneous bowel movements

Primary: Latency to Persistent Sleep (LPS) Following Single Doses of MK-1064 and Placebo — 4.27; 3.68; 2.67; 17.93 minutes

Primary: Change From Baseline in Corrected QT Interval Using Fridericia's Correction (QTcF) at Trastuzumab Steady State — -8.4 milliseconds (msec)

Primary: 1-year Survival — 38 percentage of participants

Primary: Incidence of Histologically-confirmed Cervical Intraepithelial Neoplasia (CIN) for Participants of All Ages in Denmark — 164.2; 191.4; 217.7; 240.3 Cases per 100,000 women

Primary: Change From Baseline in Visual Analogue Scale for Pain — 3.2; 3.8; 3.1; 3.3 units on a scale

Primary: PTSD Symptoms on the PTSD Checklist (PCL) at Baseline, During Treatment, After Treatment and at 2-Month Follow-up — 63.6; 58.8; 63.9; 61.7 units on a scale

Primary: Alcohol Craving in Response to the Alcohol Cue Script — 12.7; 10.7 Units on a scale

Primary: Radiographic Response — 27.8 percentage of participants

Primary: Change From Baseline in Target Area Hair Count (TAHC) — 131.3; 140.4; 129.0; 9.3 terminal hairs/cm2

Primary: Difference in Change in Clinic Systolic Blood Pressure From Baseline — -8.7; -1.0 mmHg

Primary: Percentage of Participants Maintaining Average Hemoglobin Concentration Within the Target Range During the Efficacy Evaluable Period (EEP) — 53.9 percentage of…

Primary: Subjects With 'Controlled Disease' ('Clear'/'Almost Clear' for Subjects w. at Least Moderate Disease at Baseline, 'Clear' for Subjects With Mild Disease at Baseline)…

Primary: Major Molecular Response (MMR) at 12 Months - With Imputation. — 27.8; 52.2 Percentage of Participants — p=0.0001